Purpose Optic pathway gliomas, which occur in 15-20% of paediatric patients with neurofibromatosis type 1, are the most common central nervous system tumour associated with this neurocutaneous disorder. The detection of optic pathway gliomas is essential for further management but is often delayed in infancy due to oligosymptomatic progression and difficulties in clinical detection. Therefore, the aim of our study was to find a clinical indicator for the presence of optic pathway gliomas in children with neurofibromatosis type 1 in order to facilitate early diagnosis and initiate further ophthalmological and neuroimaging investigations. Methods We retrospectively evaluated 70 patients (mean age of 10.5 years; SD of 4.3 years; range of 0.5-19.6 years; 35 females) with neurofibromatosis type 1 seen at the University Children's Hospital of Bern, Switzerland, between January 1998 and December 2008 regarding clinical features of neurofibromatosis type 1 in relation to the presence of optic pathway gliomas. Results Fifty-seven of the 70 patients (81.4%) had no clinical or radiological signs of optic pathway gliomas [magnetic resonance imaging (MRI) of the brain in 26/57], whereas 13/70 patients (18.6%) were diagnosed with optic pathway gliomas by MRI. Patients with optic pathway gliomas showed macrocephaly significantly more often compared to patients without optic pathway gliomas (8/13 vs. 9/57, respectively; p=0.004). Conclusion Macrocephaly significantly correlates with the incidence of optic pathway gliomas in children with neurofibromatosis type 1. We therefore hypothesise that in otherwise asymptomatic patients, macrocephaly is an additional indicator for performing MRI to detect optic pathway gliomas.
Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous genetic disorder occurring with an estimated incidence of 1:3,000 individuals per year, independent of ethnicity, race and gender [1] . The hallmarks of the clinical condition are the development of pigmentary lesions (café-au-lait spots, skinfold freckling and Lisch nodules), distinctive skeletal lesions (sphenoid dysplasia and pseudoarthrosis) and tumours, such as optic pathway gliomas and neurofibromas [2] .
The NF1 gene product, neurofibromin, is known to act as a tumour suppressor [3] . Loss of neurofibromin leads to increased activity of the Ras signalling pathway and therefore to accelerated cell growth with astrocyte proliferation [3, 4] . However, in the developing brain, the NF1 gene also functions as a cell growth regulator and seems to play a role in neuronal differentiation [5] . Disturbed cell growth regulation might be the backbone of an abnormal brain development, as seen in the 20% rate of learning disabilities in paediatric NF1 patients [6] .
Optic pathway gliomas (OPGs) are the predominant cerebral tumour in NF1, affecting 15-20% of all children with NF1 within their first decade of life [7] . Histologically, OPGs are almost uniformly pilocytic astrocytomas (WHO grade I). Many of these tumours show prolonged indolent phases, whereas others progress rapidly. In addition, OPGs can have erratic growth patterns or may demonstrate spontaneous regression [8, 9] . However, only 30-50% of children with NF1 and OPGs develop clinical symptoms such as decreased visual acuity, proptosis or precocious puberty, thus making an early diagnosis difficult [10] .
In an attempt to facilitate early diagnosis of OPGs in asymptomatic and oligosymptomatic children with NF1, the present study analysed clinical characteristics such as macrocephaly, epilepsy, headache/migraine, scoliosis, neurocognitive deficits and behavioural abnormalities in order to determine additional indicators for early ophthalmologic and neuroimaging investigations.
Materials and methods
This study complied with Health Insurance Portability and Accountability Act and was approved by our institutional review board. In addition, the requirement for an informed consent was waived. The current study is a retrospective review of all consecutive paediatric and adolescent patients with NF1 referred to the University Children's Hospital in Bern, Switzerland, between 1 January 1998 and 31 December 2008. On a routine basis, these children were seen over a yearly schedule by a neuropaediatrician and an ophthalmologist. Study enrolment required that the subjects fulfilled the diagnostic criteria of the 1988 National Institutes of Health (NIH) Consensus Development Conference for Neurofibromatosis Type 1 [2] . Patient charts and radiology records were reviewed for data relating to patient demographics, the clinical distribution of NIH criteria (café-au-lait spots, skinfold freckling, Lisch nodules, skeletal dysplasia, neurofibromas, optic pathway gliomas and a first-degree relative who was positive for NF1) and the presence of NF1-related neurological abnormalities (macrocephaly, epilepsy, headache/migraine, scoliosis and neurocognitive deficits such as learning deficits and behavioural abnormalities).
Patients were further divided into two groups: children with NF1 without OPGs (group 1) and children with NF1 and the presence of OPGs (group 2). OPGs were solely diagnosed by magnetic resonance imaging (MRI) of the brain. Imaging techniques were performed by clinical indication in children with symptoms or medical findings in a routine examination that required further investigation (e.g. headache, neurological abnormalities or decreased visual acuity). All images were reviewed at the time of imaging by an experienced neuroradiologist for the presence of OPGs or other brain tumours. At the time of study accomplishment, the images were re-evaluated regarding a ventricle/parenchyma ratio by measuring the cross diameter of the third ventricle at the level of the thalami and the cross diameter of the parenchyma at the level of the foramina of Monro to differentiate hydrocephalus from megalencephaly. Furthermore, tumours were classified radiologically according to the number and location. Diagnosed patients with OPG were further evaluated regarding symptoms related to OPG and the initiated therapy. Using the Student's t test for the ventricle/parenchyma ratio and the Barnard's test for the remaining calculations, we calculated possible differences among the variables between the two patient groups [11] . The null hypothesis was that both groups are equal. The hypothesis was rejected if p<0.05 in a two-tailed analysis (Tables 1, 2 and 3) .
Results
During the 10-year study period, 70 children [mean age at last follow-up of 10.5 years; standard deviation (SD) of 4.3 years; range of 0.5-19.6 years; 35 females] with NF1 were referred to the University Children's Hospital in Bern. MRI was performed in 55.7% (39/70) of the participating patients, broken down as 45.6% (26/57) of group 1 patients and all patients of group 2 (13/13). Fifty-seven of the 70 (81.4%) patients had no clinical or radiological evidence of OPGs (group 1, mean age at last presentation of 10.6 years; SD of 4.6 years; 29 females), whereas 13/70 (18.6%) patients were diagnosed with OPG by MRI of the brain (group 2, mean age at last presentation of 10.1 years; SD of 3.4 years; six females) ( Table 1 ). There was no significant difference between the groups regarding the distribution of NIH criteria, except for the presence of OPGs (Table 1) .
However, 15.8% of group 1 patients showed macrocephaly compared to 61.5% of group 2 patients. This difference was statistically significant (p=0.004) ( Table 2) . In group 1 patients with macrocephaly, two of nine (7.7%) had an MRI of the brain, whereas 24/48 (54.2%) group 1 patients without macrocephaly had an MRI of the brain (p= 0.189) ( Table 3) . Limiting the number to children who have had MRI of the brain shows that 2/26 (7.7%) group 1 patients had macrocephaly, whereas 8/13 (61.5%) group 2 patients had macrocephaly. This difference was still statistically significant (p=0.0001) ( Table 4) . Evaluating the ventricle/parenchyma ratio at the level of the third ventricle of group 1 (measured in 21/26) and group 2 (measured in 11/13) patients showed no statistical significance (0.22 vs. 0.26; p=0.620). In two of two (100%) group 1 patients with macrocephaly, unknown bright objects (UBOs) were identified on the MRI of the brain, while only 13/24 (54.2%) group 1 patients without macrocephaly had UBOs on the MRI of the brain (p=0.365) ( Table 3) . Group 2 patients with and without macrocephaly did not show any differences regarding the presence of UBOs (87.5% vs. 80.0%; p=0.849) ( Table 3 ). In addition, there were no statistically significant differences regarding epilepsy, headache/migraine, scoliosis, learning disabilities and behavioural abnormalities (Table 2) . Regarding the presence of OPGs, 10/13 (76.9%) group 2 patients had chiasmal OPGs, whereas 4/13 (30.7%) had OPGs involving one optic nerve or both optic nerves, separately, and 2/13 (15.4%) group 2 patients showed OPGs affecting the optic tract. Six of 13 (46.2%) patients initially presented with visual impairment, and 2/13 (15.4%) showed elevated intracranial pressure due to additional cerebral gliomas. However, 5/13 (38.5%) patients of group 2 were asymptomatic.
Chemotherapeutic treatment with drugs (carboplatin, etoposide and temozolamide) was started in 3/13 (23.1%) patients due to progressive visual impairment. These patients were between 9 and 10 years of age at the last follow-up, and all had significant visual impairment (visual acuity <0.3). The remaining patients showed no, or mild, visual impairment.
Discussion
The aim of our study was to find besides visual problems a clinical indicator for the presence of OPGs in paediatric patients with NF1 in order to facilitate early diagnosis and to initiate MRI of the brain as early as necessary. Our results show that macrocephaly correlates significantly with the presence of OPGs in paediatric patients with NF1, whom are also otherwise asymptomatic patients. Macrocephaly, defined as a head circumference two or more standard deviations above the sex-and age-matched population's mean, has clearly been associated with NF1, occurring in 25-50% of all patients with NF1 [12] [13] [14] . Macrocephaly was revealed in 24% of patients in our cohort. However, 61.5% of NF1 patients with OPGs demonstrated macrocephaly, whereas only 15.8% of NF1 patients without OPGs had macrocephaly. Neuroimaging of all the patients might have increased the number of patients with OPG. However, our results were still significant limiting the number to children who have had MRI of the brain. The likelihood of developing OPG after normal MRI of the brain and careful clinical and ophthalmological follow-up must be considered minimal.
In NF1, macrocephaly is caused by megalencephaly, which is defined as the enlargement of brain tissue [12] . This enlargement is mainly due to a significant increase in white matter volume when compared to normocephalic NF1 patients [12] . In addition to brain enlargement, 60-70% of NF1 patients show so-called UBOs in the brain tissue that are characteristic focal lesions of increased signal intensity on T2-weighted MRIs [14, 15] . These lesions reflect dysplastic glial proliferations in the developing brain [15, 16] and are significantly related to lower IQs in NF1-affected children [15, 17] . Thus far, only Steen et al. could demonstrate a correlation between the presence of bilateral UBOs and macrocephaly in paediatric patients with NF1 [12] . In the present study, UBOs were more frequently seen in patients with than without OPGs, but this difference was not statistically significant because of the small patient number. In summary, these NF1-specific alterations suggest that children with macrocephaly, UBOs and OPGs might have lower levels of neurofibromin and therefore more pronounced accelerated cell growth. Moreover, Szudek et al. studied statistical associations among 13 of the most important and common clinical features in NF1 [18] . It was reported that macrocephaly and OPGs have strong associations, suggesting that glial hyperplasia is responsible not only for macrocephaly but also for the development of optic pathway gliomas [13, 18, 19] .
Currently, routine neuroimaging screening for OPGs in asymptomatic paediatric patients is not recommended [20] . However, children younger than 6 years of age are at the greatest risk of OPG development [7] . In this age group, the expression of decreased visual acuity, as the most common clinical symptom in patients with OPGs, is unreliable [20] .
Limitations of our study must be acknowledged. Data were collected retrospectively, and imaging techniques were not performed in all 70 patients. Therefore, it might be possible that some undiagnosed patients with OPGs were false subjects of group 1. Furthermore, the number of participants in the present study was quite small, so larger studies are necessary to confirm our findings. We conclude that macrocephaly may be useful as a quick and inexpensive indicator for performing an MRI of the brain or thorough ophthalmological investigations in otherwise asymptomatic paediatric patients with NF1 to scan for OPGs.
